Susanne Embleton - Pharming Group Investor Mang
| PHGUF Stock | USD 0.76 0.01 1.33% |
Insider
Susanne Embleton is Investor Mang of Pharming Group NV
| Phone | 31 71 524 7400 |
| Web | https://www.pharming.com |
Pharming Group Management Efficiency
The company has return on total asset (ROA) of 0.0643 % which means that it generated a profit of $0.0643 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1669 %, meaning that it generated $0.1669 on every $100 dollars invested by stockholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Feng Chen | IGG Inc | 50 | |
| Eric Tse | Sino Biopharmaceutical Limited | 27 | |
| FCS FCIS | IGG Inc | 68 | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 |
Pharming Group NV Leadership Team
Elected by the shareholders, the Pharming Group's board of directors comprises two types of representatives: Pharming Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharming. The board's role is to monitor Pharming Group's management team and ensure that shareholders' interests are well served. Pharming Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharming Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bruno Giannetti, Member of the Management Board, Chief Operations Officer | ||
| Susanne Embleton, Investor Mang | ||
| Jeroen Wakkerman, Chief Officer | ||
| Ruud Outersterp, Chief Officer | ||
| Stephen Toor, Chief Americas | ||
| Anurag Relan, Chief Officer | ||
| MBA MD, CEO Pres | ||
| Mireille MSc, Chief Officer |
Pharming Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pharming Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.